Ann: Investor Presentation, page-13

It seems that people have simply invested money they couldn't afford to lose. Biostocks are a gamble at best and the delays reflect the politics and bureaucracy in this space. I work in software development startups, which are essentially (if done right) run like science experiments, test/measure/learn/repeat.

They have had more than fair reasons to delay trials and, in my opinion, communicated well to shareholders.

If even one of these, very safe and effective products comes to market, the payoff is potentially in the 100x + arena. The other positive is companies/teams, who have successfully delivered a drug to market are more likely to see fairer treatment on additional products. So the way I see it, if we get one across the line, the rest could be dominos.

ASX:SRX was a slow burn but then a wild ride from $2.20 - $42, and I was a late-stage investor.